Skip to content
DataLookout
Menu

MIS51ONNCT03992430

A Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) (MIS51ON)

StatusCompleted
PhasePhase 3
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 29 versions: 28 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 12 words Show 4 more changesShow less
    • Trial completed
    • Primary completion date changed from estimate of Oct 31, 2026 to Sep 7, 2026
    • Secondary endpoints: details revised at 1 of 7 entries
    • Site details revised at 11 of 59 sites
  2. Notable Primary and study completion dates: Nov 30, 2024 to Oct 31, 2026v27 Show 4 more changesShow less
    • Eligibility criteria expanded, about 10 words
    • Primary endpoints: 2 to 3
    • Secondary endpoints revised (7)
    • Study title shortened, about 1 word
  3. Minor Study sites: 58 to 59v26
  4. Minor Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 154 to confirmed 160
    • Study sites: 60 to 58
    v25
  5. Minor Study sites: 54 to 60v24
Show 22 earlier versionsHide 22 earlier versions
  1. Minor Study sites: 51 to 54v23
  2. Minor Study sites: 50 to 51v22
  3. Minor Study sites: 52 to 50v21
  4. Minor Study sites: 51 to 52v20
  5. Minor Study sites: 48 to 51v19
  6. Minor Study sites: 45 to 48v18
  7. Minor Study sites: 30 to 45v17
  8. Minor Study sites: 28 to 30v16
  9. Minor Study sites: 23 to 28v15
  10. Minor Study sites: 21 to 23v14
  11. Minor Study sites: 18 to 21v13
  12. Minor Study sites: 15 to 18v12
  13. Minor Study sites: 13 to 15v11
  14. Notable Primary and study completion dates: Feb 28, 2026 to Nov 30, 2024
    • Study sites: 10 to 13
    v10
  15. Minor Study sites: 8 to 10v9
  16. Notable Trial status: Active, Not Recruiting to Recruitingv8 Show 7 more changesShow less
    • Eligibility criteria expanded, about 85 words
    • Primary endpoints: 5 to 2
    • Enrollment target: 152 to 154
    • Primary and study completion dates: Feb 2026 to Feb 28, 2026
    • Secondary endpoints: 6 to 7
    • Study sites revised (8)
    • Study title expanded, about 1 word
  17. Notable Primary and study completion dates: Oct 2024 to Feb 2026
    • Trial status: Recruiting to Active, Not Recruiting
    • Study sites: 7 to 8
    v7
  18. Minor Site contacts updated at 1 of 7 sitesv6
  19. Notable Start date changed from estimate of Jan 2020 to Jul 13, 2020
    • Eligibility criteria expanded, about 15 words
    • Study sites: 2 to 7
    • Secondary endpoints: details revised at 1 of 6 entries
    v5
  20. Minor Study sites: 1 to 2
    • Start date: Dec 2019 to Jan 2020
    v4
  21. Minor Start date: Dec 5, 2019 to Dec 2019v3
  22. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date: Aug 2019 to Dec 5, 2019
    • Study sites: 0 to 1
    • Study title expanded, about 1 word
    v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Part 1: Incidence of Adverse Events (AEs)
Timeframe: Up to Week 148
Part 2: Change From Baseline at Week 144 in the NSAA Total Score (for Final Analysis)
Timeframe: Baseline, Week 144
Part 2: Change from Baseline at Week 72 or Week 96 in NSAA Total Score (for Conditional Efficacy Interim Analysis)
Timeframe: Baseline, Week 72 or Week 96

Secondary (7)

Part 2: Change From Baseline in Time to Rise From the Floor, Time to Complete 10-Meter Walk/Run, and the Timed Stair Ascend Test
Part 2: Change From Baseline in the Total Distance Walked During 6-Minute Walk Test (6MWT)
Part 2: Change from Baseline at Week 144 in Forced Vital Capacity Percent Predicted (FVC%p)
Part 2: Time to Loss of Ambulation (LOA)
Part 2: Change From Baseline in Skeletal Muscle Dystrophin Expression
Show 2 moreShow less
Part 2: Incidence of Adverse Events (AEs)
Part 2: Pharmacokinetic (PK) Plasma Concentration of Eteplirsen

Arms and interventions

Part 1: EteplirsenExperimental

Participants will receive eteplirsen 100 mg/kg once weekly for at least 4 weeks, followed by eteplirsen 200 mg/kg once weekly for at least 4 weeks.

Part 2: Eteplirsen 30 mg/kgActive comparator

Randomized participants will receive eteplirsen 30 mg/kg once weekly for up to 144 weeks.

Part 2: Eteplirsen 100 mg/kgExperimental

Randomized participants will receive eteplirsen 100 mg/kg once weekly for up to 144 weeks.

Part 2: Eteplirsen 200 mg/kgExperimental

Randomized participants will receive eteplirsen 200 mg/kg once weekly for up to 144 weeks.

Drugs: Eteplirsen

Sites

59 sites in 26 countries

India 8, Jordan 4, South Korea 4, Colombia 3, France 3, Germany 3, Serbia 3, United Kingdom 3, United States 3, Czechia 2, Italy 2, Mexico 2, Netherlands 2, Norway 2, Spain 2, Taiwan 2, Turkey (Türkiye) 2, Denmark 1, Greece 1, Hungary 1, Ireland 1, New Zealand 1, Poland 1, Romania 1, Slovenia 1, Switzerland 1